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Background. We report health-related QoL (HRQoL) from GRACE (Gender, Race, And Clinical Experience) study by sex and
race over 48 weeks. Methods. 429 treatment-experienced adults (HIV-1 RNA ≥ 1000 copies/mL) received darunavir/ritonavir
600/100mg twice daily plus an appropriate background regimen. QoL was measured by the Functional Assessment of HIV
Infection (FAHI) questionnaire. Results. 67% women and 77% men, including 67.4% black, 76.0% Hispanic, and 73.8% white
patients, completed the trial. Baseline total FAHI scores were similar between sexes and races. Total FAHI of the entire population
improved byWeek 4 (P < .05); near-maximum changes obtained byWeek 12 weremaintained throughWeek 48.Women and black
patients demonstrated larger improvements in total FAHI versus men, and Hispanic and white patients, respectively. Conclusion.
HRQoL improved in all sex and racial/ethnic groups. Sex-based and race-based diﬀerences in improvements in FAHI subscales
may provide insight into subtle diﬀerences of HIV-1 and treatment on HRQoL in diﬀerent populations.
1. Introduction
Improvements in antiretroviral (ARV) therapy have in-
creased the life expectancy of patients with HIV-1 infection,
andHIV is now considered amanageable chronic disease [1].
The maintenance of a high quality of life (QoL), as well as
optimization of physical, emotional, and social health, is an
important aspect of disease management for HIV-1–infected
patients. Health-related quality of life (HRQoL)measures are
used to quantify the physical and mental aspects of HIV-
1 infection that can impact a patient’s overall well-being.
Additionally, several studies have demonstrated a correlation
between HRQoL and survival of HIV-1–infected patients
[2–4], highlighting the need for monitoring and optimiz-
ing HRQoL. The GRACE (Gender, Race, And Clinical
Experience) study was designed to investigate sex-based and
race-based diﬀerences in outcomes with darunavir/ritonavir-
(DRV/r-) based therapy in treatment-experienced patients.
The primary outcomes of the GRACE study have been
reported [5]. Here, we report the HRQoL results from
GRACE by sex and race over 48 weeks.
2. Methods
2.1. Study Design and Patients. GRACEwas a 48-week, open-
label, Phase IIIb study conducted at 65 study sites across
the United States, Canada, and Puerto Rico. Treatment-
experienced adults (HIV-1 RNA ≥ 1000 copies/mL) received
DRV/r 600/100mg twice daily plus an appropriate ARV
background regimen, chosen on the basis of resistance testing
[5]. Details of the study design and the primary outcomes of
the GRACE study have been reported elsewhere [5]. Human
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experimentation guidelines of the US Department of Health
and Human Services were followed in the conduct of this
clinical research, the research protocol was reviewed and
approved by institutional review boards for all 65 study sites,
and all participants provided written informed consent.
2.2. Study Evaluations. Health-related QoL was measured
by the Functional Assessment of HIV Infection (FAHI)
questionnaire, which contained 47 questions measuring
five functional subscales [6, 7]: physical (PWB), emotional
(EWB), functional and global (FGWB), and social (SWB)
well-being, as well as cognitive functioning (CF). The range
of possible scores for each subscale was as follows: PWB and
EWB, 0 to 40; FGWB, 0 to 52; SWB, 0 to 32; CF, 0 to 12.
The total FAHI score, with possible scores ranging from 0
to 176, was calculated as the sum of all five subscale values,
with higher scores indicating better results. Each subject
completed the FAHI questionnaire at the beginning of the
study visit, before other assessments, at study entry, and at
weeks 4, 12, 24, and 48 or at early withdrawal. Questionnaires
completed at early withdrawal visits were not included in the
analyses. The time recall period was the previous 7 days. Post
hoc analyses were conducted in order to investigate factors
that were associated with improvement in total FAHI score
over 48 weeks.
2.3. Statistical Analyses. Analyses were performed on the
observed population. Imputed values were derived for each
of the five subscales of the FAHI questionnaire. Imputed
values were calculated if at least 50% of the items in that
subscale were present using the mean of the other items
in the subscale, rounded to the nearest integer; if greater
than 50% of the items in a given subscale were missing,
no imputation was calculated. Results from intention-to-
treat–last-observation-carried-forward analyses were similar
to results obtained from the observed population and are not
presented here.
In the post hoc analysis that investigated factors associ-
ated with improvement in total FAHI score, 18 covariates
were evaluated using a repeated measure analysis; covariates
significant at the P < .10 level were considered for the mul-
tivariate analysis. The multivariate analysis was performed
using a forward stepwise selection with stay criteria of P <
.05. If two or more covariates selected from the univariate
analyses were highly correlated, only the most significant was
considered for inclusion in the multivariate models to avoid
issues with collinearity.
3. Results
3.1. Patient Population and Baseline Characteristics. The
GRACE study enrolled 429 patients, of whom 66.9% were
women, 61.5% were black, 22.4% were Hispanic, and 15.2%
were white. In the intent-to-treat population, overall, 53.4%
achieved virologic response (HIV RNA < 50 copies/mL;
women, 50.9%; men, 58.5%; black, 48.5%; Hispanic, 61.5%;
white, 60.0%) [5, 8]. In the time-to-loss of virologic
response–non-virologic-failure censored analysis of the over-
all population that censored patients who discontinued
for reasons other than virologic failure, 73.2% of patients
(women, 73.0%;men, 73.5%; black, 68.8%; Hispanic, 79.7%;
white, 78.0%) achieved virologic response [5, 8].
The HRQoL analysis included the 193 women (67%) and
109 men (77%) who completed the trial (Figure 1(a)). By
race, 178 black (67.4%), 73 Hispanic (76.0%), and 48 white
(73.8%) patients completed the trial (Figure 1(b)). Women
had a higher rate of discontinuation compared with men,
mostly due to reasons other than virologic failure, and black
patients had a higher rate of discontinuation compared with
Hispanic and white patients, mostly due to loss to followup
and other reasons (Figures 1(a) and 1(b)).
At baseline, women were younger and had a higher
average body mass index than men (Table 1). Men and
black patients had more advanced disease at baseline than
women and Hispanic or white patients, respectively, with
lower median CD4+ counts and higher proportions of US
Centers for Disease Control and Prevention Class C disease
(Table 1). Four patients who self-identified as Asian or other
race were not included in the analyses by race due to their
low numbers.
3.2. Health-Related Quality of Life: Total Functional Assess-
ment of HIV Infection Score. At baseline, the total FAHI
scores for the overall population ranged from 26 to 176.
Women had slightly lower total FAHI scores compared
with men (116.8 versus 120.8), and Hispanic patients had
slightly lower total scores compared with black or white
patients (114.1, 119.5, and 119.5, resp.; Figure 2); neither
sex-based nor race-based diﬀerences in baseline scores
were statistically significant. The total FAHI score of the
entire GRACE population improved significantly by Week
4 (Figure 2(a)). Near-maximum changes were achieved by
Week 12 and were maintained through Week 48. Similar
patterns of improvement were observed for both sexes and
all races (Figures 2(b) and 2(c)).Women demonstrated larger
improvements in total FAHI scores compared with men, and
black patients demonstrated larger improvements compared
with Hispanic and white patients. Overall, only 3% of the
subscales were imputed for missing data.
The post hoc repeated measure analysis to investigate
factors associated with improved FAHI over 48 weeks
identified five factors with P < .10 (Table 2) that were
considered for the multivariate analysis. The post hoc
multivariate analysis subsequently identified lower baseline
FAHI score, lower baseline CD4+ cell count, confirmed
virologic response, and analysis time point as significantly
associated with improvement in FAHI score over 48 weeks
(Table 3). Notably, neither sex nor race was found to be
significant in the final model, and there was no interaction
between the two variables.
In a post hoc sensitivity analysis, it was noted that
patients with lower baseline FAHI scores were significantly
more likely to discontinue (P = .044) than patients with
higher baseline HRQoL scores. To assess the impact of
discontinuations, an additional post hoc sensitivity analysis
evaluated only patients who completed the trial. When
patients who discontinued the trial were excluded and
only patients who completed the trial were analyzed, the
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Patients receiving
treatment
(N = 429)
Men discontinued (n = 33; 23.2%)Women discontinued (n = 94; 32.8%)
Men completed (n = 109; 76.8%)
Women (n = 287; 66.9%) Men (n = 142; 33.1%)
(I) Lost to followup (n = 9; 6.3%)
(II) Adverse events (n = 6; 4.2%)
(III) Withdrew consent (n = 6; 4.2%)
(IV) Noncompliance (n = 6; 4.2%)
(V) Virologic failure (n = 4; 2.8%)
(VI) Other (n = 2; 1.4%)a
(a) Ineligible to continue (n = 1)
(b) Site closed (n = 1)
(I) Lost to followup (n = 24; 8.4%)
(II) Adverse events (n = 22; 7.7%)
(III) Withdrew consent (n = 13; 4.5%)
(IV) Noncompliance (n = 13; 4.5%)
(V) Virologic failure (n = 6; 2.1%)
(VI) Other (n = 16; 5.6%)a
(a) Site closed (n = 3)
(b) Pregnant (n = 2)
(c) Ineligible to continue (n = 2)
(d) Patient moved (n = 2)
(e) Did not attend visits (n = 2)
(f) Sponsor’s decision (n = 1)
(g) Safety (n = 1)b
(h) No decrease in viral load (n = 1)
(i) Time restraints on visits (n = 1)
(j) Started a new ARV regimen (n = 1)
Women completed (n = 193; 67.2%)
(a)
Patients receiving
treatment
(N = 429)
Patients included in
analysis
(n = 425)
Hispanic patients discontinued
(n = 23; 24
Black patients discontinued
(n=86; 32.6%)
Black patients completed
(n = 178; 67.4%)
White patients completed
(n = 48; 73.8%)
Hispanic patients completed
(n = 73; 76.0%)
Black patients
(n = 264; 61.5%)
White patients
(n = 65; 15.2%)
Hispanic patients
(n = 96; 22.4%)
Patients excluded from analysis
(self-identified as Asian or Other)
(n = 4)
White patients discontinued
(n = 17; 26.2%)
(I) Lost to followup (n = 3; 4.6%)
(II) Adverse events (n = 5; 7.7%)
(III) Noncompliance (n = 2; 3.1%)
(IV) Withdrew consent (n = 3; 4.6%)
(V) Virologic failure (n = 2; 3.1%)
(VI) Other (n = 2; 3.1%)a
(a) Pregnant (n = 1)
(b) Ineligible to continue (n = 1)
(I) Lost to followup (n = 5; 5.2%)
(II) Adverse events (n = 6; 6.3%)
(III) Noncompliance (n = 4; 4.2%)
(IV) Withdrew consent (n = 4; 4.2%)
(VI) Other (n = 3; 3.1%)a
(a) Pregnant (n = 1)
(b) Ineligible to continue (n = 1)
(c) Did not attend visits (n = 1)
(I) Lost to followup (n = 24; 9.1%)
(II) Adverse events (n = 17; 6.4%)
(III) Noncompliance (n = 13; 4.9%)
(IV) Withdrew consent (n = 12; 4.5%)
(V) Virologic failure (n = 7; 2.7%)
(VI) Other (n = 13; 4.9%)a
(a) Site closed (n = 4)
(b) Patient moved (n = 2)
(c) Did not attend visits (n = 1)
(d) Ineligible to continue (n = 1)
(e) Safety (n = 1)b
(f) No decrease in viral load (n = 1)
(g) Time restraints on visits (n = 1)
(h) Started a new ARV (n = 1)
(i) Sponsor’s decision (n = 1)
(V) Virologic failure (n = 1; 1.0%)
.0%)
(b)
Figure 1: Study disposition by (a) sex and (b) race. a“Other” classification was selected by the investigator as reason for discontinuation.
bOlder patient taking too many concomitant medications; ARV: antiretroviral.
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Table 1: Baseline demographics and disease characteristics by sex and racea.
Parameter Women
n = 287 Men n = 142
Black
n = 264
Hispanic
n = 96
White
n = 65
Age, mean (SE), years 41.7 (0.63) 45.2 (0.75) 43.0 (0.62) 40.3 (1.05) 45.5 (1.13)
Gender, n (%)
Female 287 (100) — 191 (72.3) 60 (62.5) 34 (52.3)
Male — 142 (100) 73 (27.7) 36 (37.5) 31 (47.7)
BMI, mean (SE), kg/m2 28.2 (0.44) 25.4 (0.42) 27.6 (0.44) 26.8 (0.58) 26.7 (0.88)
Duration of infection, mean (SE), years 10.9 (0.32) 12.2 (0.49) 11.0 (0.34) 10.5 (0.58) 13.8 (0.66)
Viral load, mean (SE), log10 copies/mL 4.65 (0.05) 4.73 (0.07) 4.66 (0.06) 4.68 (0.09) 4.73 (0.10)
CD4+ count, median (range), cells/mm3 210 (1, 868) 175 (2, 1125) 179 (1, 868) 208 (1, 1125) 249 (6, 826)
CDC Class C, n (%) 102 (35.5) 67 (47.2) 111 (42.0) 33 (34.4) 22 (33.8)
Prior use of ≥2 PIs, n (%) 168 (58.5) 92 (64.8) 156 (59.1) 60 (62.5) 42 (64.6)
PSS of the OBRb, mean (SD) 2.0 (0.65) 2.0 (0.81) 2.0 (0.72) 1.9 (0.67) 2.0 (0.67)
Hepatitis B surface antigen (positive), n (%) 12 (4.2) 7 (4.9) 15 (5.7) 3 (3.1) 1 (1.5)
Hepatitis C antibody (positive), n (%) 39 (13.6) 25 (17.6) 41 (15.5) 12 (12.5) 11 (16.9)
a
Two women and two men self-identified as Asian or other and were not included in the analysis by race. bBy virco TYPE; SE: standard error; BMI: body mass
index; CDC: Centers for Disease Control and Prevention; PI: protease inhibitor; PSS: phenotypic susceptibility score; OBR: optimized background regimen;
SD: standard deviation.
Table 2: Results from the univariate analysis to investigate factors
associated with improvements in total FAHI score over 48 weeks.
Covariate P value
Baseline FAHI <.0001
Baseline CD4+ count .0052
Confirmed virologic response .0335
History of psychological illness .0570
Baseline log10 viral load .0862
Stage of HIV infection .1441
Sex .1979
Presence of etravirine in the OBR .2062
Alcohol use .2700
Duration of diagnosis .2995
Black race versus other .3490
Incidence of grade 2–4 AE .4374
Smoker .5272
Presence of hepatitis C antibody .5938
Age .7183
Structured treatment interruption .7757
Adherence .8049
Drug use .9548
FAHI: Functional Assessment of HIV Infection; OBR: optimized back-
ground regimen; AE: adverse event.
total FAHI score still improved from baseline to Week 48
(Figure 2(a)) to a similar extent as in the total population.
3.3. Health-Related Quality of Life: Functional Assessment
of HIV Infection Subscales. The EWB and PWB subscales
showed significant changes from baseline to Week 12, which
were maintained throughWeek 48 for the overall population
and across all sex and race subgroups (Table 4). Women
Table 3: Factors associated with improvements in total FAHI score
over 48 weeks in the final multivariate model.
Covariate P value
Lower baseline FAHI <.0001
Confirmed virologic response .0045
Analysis time pointa .0002
Lower baseline CD4+ count .0077
a
Total FAHI score increases over time; FAHI: Functional Assessment of HIV
Infection.
and black patients demonstrated the largest changes in EWB
compared with the other subgroups. The FGWB and SWB
subscales showed small improvements from baseline through
Week 48 overall. Changes in the FGWB subscale were only
significant for women and black patients (Table 4). The CF
subscale values did not change over 48 weeks for the overall
population, or for any of the sex and race subgroups.
4. Discussion
Many factors can impact the HRQoL of patients with HIV-1,
including the tolerability of diﬀerent ARV agents. Diﬀerences
in safety/tolerability, pharmacokinetic parameters, and/or
eﬃcacy of ARVs could potentially contribute to sex-based
or race-based diﬀerences in HRQoL scores. To date, studies
investigating sex-based and race-based diﬀerences in HRQoL
for HIV-1–infected patients have reported conflicting results
[9–12]. In the GRACE study, HRQoL significantly improved
for all participants. Near-maximal improvements were
reached by Week 12 and were maintained through Week 48.
When only patients who completed the trial were analyzed,
similar improvements in total FAHI score over time were
still seen, suggesting that the improvements in the overall
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Figure 2: Mean change from baseline in total FAHI score in (a) the overall population and completersa, (b) by sex, and (c) by raceb
(observed). ∗Statistically significant change from baseline (P < .05). aExcludes patients who discontinued the trial. bFour patients self-
identified as Asian or other and were not included in the analysis by race due to small sample size; FAHI: functional assessment of HIV
infection.
population were not an artifact of patients with low HRQoL
scores discontinuing the trial.
All sex and racial/ethnic groups demonstrated improve-
ments in HRQoL over 48 weeks. These results are consistent
with those from a previous study of 1178 patients receiving
ARV therapy, which also showed that HRQoL improved
over time, regardless of sex [11]. In univariate assessments,
the largest improvements in total FAHI scores were seen
in women and black patients, despite the fact that these
two groups both had lower virologic response rates and
higher discontinuation rates compared with men and with
Hispanic and white patients, respectively. The diﬀerences
seen here in total FAHI scores were driven by the larger
increases in the EWB and FGWB subscales for women and
black patients compared with the other subgroups. The post
hoc multivariate analysis, however, found that neither black
race nor sex was significantly associated with improved total
FAHI scores over 48 weeks. Given that sex and race were
not associated with improved total FAHI in the multivariate
analysis, it is likely that diﬀerences in the change in HRQoL
by sex and race were at least partially driven by diﬀerences in
baseline characteristics, such as disease severity. These results
are in agreement with those from another study of 287 HIV-
1–infected women who completed a HRQoL assessment
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Table 4: Mean change from baseline in FAHI questionnaire subscales (observeda).
n Overall n Women n Men n Black n Hispanic n White
PWB
BL 424 29.4 283 28.8 141 30.6 262 29.5 94 29.7 64 29.0
Wk 12Δ 359 2.6b 236 2.7b 123 2.3b 218 2.6b 82 2.6b 55 2.2b
Wk 48Δ 298 2.2b 190 2.3b 108 2.0b 176 2.3b 71 2.1b 48 1.8b
EWB
BL 423 25.1 283 24.5 140 26.5 261 25.4 94 23.3 64 26.7
Wk 12Δ 358 3.1b 235 3.6b 123 2.2b 218 3.6b 82 2.1b 54 2.8b
Wk 48Δ 297 3.8b 190 4.5b 107 2.5b 175 4.1b 71 3.8b 48 2.3b
SWB
BL 423 20.5 283 20.7 140 19.9 261 21.0 94 18.5 64 21.3
Wk 12Δ 359 0.2 236 0.4 123 −0.2 218 0.2 82 −0.5 55 0.9
Wk 48Δ 296 0.5 189 0.3 107 1.0 174 0.8 71 0.1 48 0.6
CF
BL 423 8.2 283 8.0 140 8.7 261 8.3 94 8.0 64 8.2
Wk 12Δ 359 0.1 236 0.3 123 −0.2 218 0.2 82 −0.1 55 0.1
Wk 48Δ 296 −0.1 189 0.1 107 −0.4 174 0.0 71 −0.3 48 −0.2
FGWB
BL 423 34.9 283 34.8 140 35.2 261 35.4 94 34.5 64 34.3
Wk 12Δ 359 1.1b 236 1.4b 123 0.6 218 1.5b 82 0.6 55 0.5
Wk 48Δ 297 0.7 190 1.0 107 0.3 175 1.5b 71 −0.6 48 0.1
a
The n value varies for each parameter. bSignificant change (P < .05); FAHI: Functional Assessment of HIV Infection; PWB: physical well-being; BL: baseline;
Wk: week; Δ: change from baseline; EWB: emotional well-being; SWB: social well-being; CF: cognitive functioning; FGWB: functional and global well-being.
during their current treatment regimen. This study also
found that race had no bearing on HRQoL [10]; however,
changes in HRQoL over time were not assessed.
Lower baseline FAHI scores, lower baseline CD4+ cell
counts, and confirmed virologic response were identified as
significantly associated with improved total FAHI scores over
48 weeks. CD4+ cell count and general disease state have
previously been associated with absolute HRQoL scores in
other studies [10, 12, 13]. Higher CD4+ cell counts have
been linked to higher HRQoL scores in women and men
[10, 13], whereas the presence of AIDS has been linked
to lower self-perceived physical health scores in both sexes
[12]. The DUET study, which investigated the eﬃcacy and
safety of etravirine in treatment-experienced patients, also
demonstrated an association between baseline FAHI score
and CD4+ cell counts and improvement in FAHI scores over
24 weeks [14].
Results from this study suggest that DRV/r-based, opti-
mized, ARV therapy over 48 weeks results in significant
improvement in self-perceived HRQoL, regardless of sex and
race. However, due to the single-arm design of this study,
we cannot conclude whether this improvement is better
or worse than those associated with other ARV regimens.
Previous studies of sex-based and race-based diﬀerences
in HRQoL scores have demonstrated conflicting results,
with some studies noting diﬀerences in overall HRQoL
between the sexes or races and other studies reporting no
diﬀerences [9–12]. These studies, however, are limited due
to low proportions of women or people of color and/or
the enrollment of women only, with no male group for
comparison. In contrast, the large proportion of women
enrolled in GRACE, along with a suﬃcient number of men
and the large proportion of people of color, may allow more
clinically meaningful conclusions to be drawn regarding sex-
based and race-based diﬀerences in HRQoL.
Although the overall conclusions from previous studies
about sex-based or race-based diﬀerences in HRQoL are con-
tradictory, previous studies do suggest that factors aﬀecting
HRQoL scores may vary between sexes. One study showed
that longer duration of infection and low levels of social
support were linked to lower HRQoL scores in women,
whereas diﬃculty taking ARV tablets, intravenous drug use,
and low levels of social support were associated with lower
HRQoL scores in men [12]. These sex-associated diﬀerences
may make it possible to tailor HIV treatments and treatment
support to women and men, thus maximizing their overall
QoL.
In this trial, confirmed virologic response was found to
be significantly associated with improved total FAHI scores.
In the GRACE trial, women and black patients had lower
response rates and higher discontinuation rates than the
other sex and race subgroups [5]. Based on this, lower
improvements in FAHI scores in these two groups may
have been expected. However, the opposite was observed,
with women and black patients demonstrating the largest
improvements in FAHI scores over 48 weeks. These contrary
results suggest the need to measure alternative outcomes
in clinical trials, as virologic response alone may not be
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wholly indicative of a patient’s overall improvement while on
ARV therapy. The GRACE study was designed with patient
support inmind, with opportunities to apply for sponsorship
for site-specific recruitment and retention activities [15].
These activities may have contributed to the subjects’
comfort level with both treatment and study participation
and may have led to a greater sense of attachment to
site staﬀ and care delivery. It is likely that factors distinct
from virologic response may be influencing patients’ overall
HRQoL, particularly for women and black patients, and
these should be investigated in the future.
Interestingly, we found that patients with lower baseline
FAHI scores were significantly more likely to discontinue
than patients with higher baseline HRQoL scores. Although
data are lacking with regard to the association between
HRQoL and retention of patients in clinical trials, other
studies have linked lowerHRQoL scores to decreased survival
of HIV-1–infected subjects [2–4]. Furthermore, measures
of HRQoL in a large veteran outpatient population have
also been shown to predict survival more generally [16].
In the future, it may be possible to identify patients with
a higher risk of discontinuation based on their baseline
HRQoL scores; these patients could then be more closely
monitored, potentially improving retention in care. This
approach deserves further study.
5. Conclusions
The sex-based and race-based diﬀerences in the improve-
ments in total FAHI score and FAHI subscales may provide
insight into the subtly diﬀerent eﬀects of HIV-1 infection and
treatment onHRQoL in diﬀerent populations. The data from
GRACE on HRQoL by sex and race may provide valuable
information into methods resulting in future optimization
of treatments and retention in care for specific populations
of HIV-infected patients.
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